Annexon, Inc. (NASDAQ:ANNX)
| Market Cap | $650.45M+39.8% |
| Revenue (ttm) | $0 |
| Net Income | -$198.96M+3.9% |
| EPS | -$1.04+26.2% |
| Shares Out | 163.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,462,474 |
| Open | $4.13 |
| Previous Close | $4.19 |
| Day's Range | $3.88 - $4.16 |
| 52-Week Range | $2.54 - $7.18 |
| Beta | 1.44 |
| Analysts | Buy |
| Price Target | $14.00(+252.64%) |
| Earnings Date | Mar 8, 2027 |
About ANNX
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
Annexon, Inc. Stock Analysis — InsiderScore
Annexon, Inc. scored higher than 46% of companies evaluated by InsiderBuying, and ranked 35th out of 94 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Annexon, Inc. bought $99.8K of stock across 1 purchase in the last 90 days, the largest of them $99.8K.
The average purchase added about 7% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating ANNX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 8, 2027Earnings report
$ANNX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ANNX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ANNX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ANNX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ANNX Revenue by Segment
| Stock-based compensation | $5.11M | 73.39% |
| Interest and other income, net | $1.85M | 26.61% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ANNX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ANNX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ANNX
| XBIState Street SPDR S&P Biotech ETF | $25.88M |
| VTIVanguard Morningstar Total Stock Market ETF | $24.20M |
| IWMiShares Russell 2000 ETF | $16.95M |
| VXFVanguard Extended Market ETF | $8.48M |
| IWOiShares Russell 2000 Growth ETF | $6.21M |
| IBBiShares Biotechnology ETF | $5.20M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ANNX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 results reported with key Phase III milestone anticipated; concrete clinical/business progress outweighs unrelated sector commentary.
Recent Insider Activity
Insider Score Trend Over Time
-7.9 since Sep 26Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.